Is Atherosclerosis an Allergic Disease?

Christoph J. Binder, Joseph L. Witztum

IgE Stimulates Human and Mouse Arterial Cell Apoptosis and Cytokine Expression and Promotes Atherogenesis in Apoe–/– Mice

Wang et al


A new report in the Journal of Clinical Investigation adds to the ever-increasing evidence that immunological mechanisms play an important role in atherogenesis. These new observations suggest involvement of IgE and its FcεRIα receptor in the promotion of atherosclerosis, and specifically in plaque instability and clinical events.

Evidence continues to accumulate supporting an important role for immunological mechanisms in all phases of atherosclerosis.1-3 Previous studies have supported an important modulating role for disease-specific IgG and IgM and for Fcγ receptors in modulating atherogenesis.4-9 In a recent report, Wang et al contribute to this growing body of literature by presenting novel observations supporting a proatherogenic role for IgE and its high-affinity receptor FcεRIα.10 The authors compared the extent of atherosclerosis in wild-type apoE–/– mice fed a Western diet with apoE–/–/FcεRIα–/– mice and observed a profound reduction in lesion formation. Although nearly all the cell types known to be involved in atherogenesis express FcεRIα receptors in vivo, the authors focused primarily on the potential role of this receptor in macrophage biology and demonstrated that IgE mediates a variety of proinflammatory effects in macrophages, such as release of interleukin-6 and monocyte chemoattractant protein-1, as well as proteases such as cathepsins. In addition, it promotes apoptosis. In large part, these effects (particularly the induction of apoptosis) were mediated by aggregated IgE, as would occur when cross-linked by antigen, and also by an obligatory interaction of FcεRIα with Toll-like receptor 4. In particular, these observations suggest the possibility that IgE and its FcεRIα receptor on macrophages may be involved in late phases of atherosclerosis, promoting plaque instability and clinical events. The potential relevance of these findings to human disease was supported by the finding of elevated IgE levels in patients with various manifestations of cardiovascular disease (CVD), in particular in those with unstable angina and acute coronary events.

A potential role for IgE in CVD has been previously suggested by studies strongly linking mast cells to atherogenesis and aneurysm formation.11-14 By demonstrating the potential for IgE to participate in macrophage activation and promotion of apoptosis, these studies suggest that IgE may become atherogenic by interaction with IgE, particularly IgE cross-linked by antigen. The demonstration that FcεRIα receptors must interact with Toll-like receptor 4 to produce such effects adds to the growing evidence that individual innate immune receptors effect many of their biological actions by combinatorial activity with other innate receptors, as exemplified by the interactions of CD36 and Toll-like receptor 2 to mediate macrophage apoptosis.15

Such combinatorial groupings undoubtedly increase the specificity of response of a given innate receptor, perhaps providing individualized responses in different cell types or under different conditions. Likely, the proatherogenic activity of IgE in humans is more complex. In contrast to the data described by Wang et al,10 IgE binding to FcεRIα was previously reported to actually promote the survival of human monocytes,16 and in another report, it was reported to induce proinflammatory effects through the low affinity IgE receptor (CD23), including the release of interleukin-6 and thromboxane B2 in human B lymphocytes.17 Nevertheless, these studies suggest novel ways by which IgE may contribute to inflammation and destabilization of the advanced plaque and thus could be relevant to clinical disease.

In the article by Wang et al, the authors describe epidemiological studies in which IgE levels were found to be higher in subjects with CVD and, in particular, subjects experiencing unstable angina and acute coronary events.10 It is not clear at what time in relation to acute events these levels were measured, nor were control patients with other acute illness sampled. Because the prevalence of known CVD risk factors was very high in the CVD patients studied, it is not possible to determine whether the elevated IgE levels are disease associated or possibly disease causing. Furthermore, the levels of IgE measured in the patients were 150- to 300-fold higher than the concentrations of IgE used in the experimental studies in vitro, raising important questions as to the relevance to human disease of the effects studied in cell culture. Aside from the usual arguments that the localized concentrations at the surface of a macrophage in vivo may be quite different than levels in plasma, it is also possible that simultaneous activation of Toll-like receptor 4 might lead to synergistic effects. For example, one could imagine that in a setting of “metabolic endotoxemia” (in which low but ele-
vated lipopolysaccharide levels occur in some human patients, such as those with diabetes and metabolic syndrome), these ordinarily subthreshold levels of lipopolysaccharide would synergize with similarly low but elevated levels of IgE to mediate some of the described proinflammatory effects. A similar situation has been proposed for the interaction of lipopolysaccharide and minimally modified LDL with macrophages. In addition, aside from conditions in which there are generalized increases in IgE levels, such as parasitic infections and hyper-IgE syndromes, elevated IgE levels usually reflect allergic-type immune responses. It would be of great interest to know whether the increased IgE levels were associated with a polyclonal IgE response or also contain IgE against disease-specific antigens.

The report by Wang et al. and other reports describing the potential importance of mast cells to CVD have provided a compelling case to study the role of IgE in inflammatory conditions such as atherosclerosis. It adds to the growing evidence of the importance of immune function in atherogenesis and in particular of the role that immunoglobulins play, both through antigen-specific interactions and antigen-independent regulatory roles.

References

Is Atherosclerosis an Allergic Disease?
Christoph J. Binder and Joseph L. Witztum

Circ Res. 2011;109:1103-1104
doi: 10.1161/RES.0b013e31823a8c44

Circulation Research is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2011 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7330. Online ISSN: 1524-4571

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circres.ahajournals.org/content/109/10/1103

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Circulation Research can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Circulation Research is online at:
http://circres.ahajournals.org/subscriptions/